Amgen (NASDAQ:AMGN) is in a bit of a conundrum.

The big biotech's talimogene laherparepvec -- T-VEC for short -- passed its primary endpoint, lowering the durable response rate in melanoma patients. But a secondary endpoint of overall survival just missed being statistically significant, with a p-value of 0.051. The Food and Drug Administration typically likes to see a p-value of less than 0.05, which equates to less than a 5% chance that the observed difference was due to chance alone.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss Amgen's chances for success, whether it will be able to compete with Bristol-Myers Squibb's (NYSE:BMY) Yervoy, and its potential to be used in combination with Yervoy and Merck's (NYSE:MRK) anti-PD-1 antibody MK-3475.